Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Shares of Novo Nordisk ($NVO) climbed by 4% to about $47 per share on Wednesday morning even after Deutsche Bank ($DB) reaffirmed its Sell rating o...

Pharma Giant Novo Nordisk’s Stock (NVO) Jumps Even as Deutsche Bank Repeats Sell Call

Novo Nordisk ( ($NVO) ) just unveiled an update. Novo Nordisk, a Danish healthcare company specialising in treatments for serious chronic diseases ...

Novo Nordisk Advances DKK 15 Billion Share Buyback Programme Through Late August 2026

Novo Nordisk received a Sell rating and a DKK265.00 price target from Deutsche Bank analyst Emmanuel Papadakis today. Papadakis covers the Healthca...

Novo Nordisk (0QIU) was downgraded to a Sell Rating at Deutsche Bank

Some companies view obesity medications as optional treatments. 


Eli Lilly Stock (LLY) Rattled as Companies Decline to Cover Weight-Loss Drug Costs

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The AMAZE 7 study, officially titled “Efficacy and Safety of Zenagamtide s...

Novo Nordisk’s AMAZE 7 Trial Pits Next-Gen Obesity Drug Against Semaglutide

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novo Nordisk today and set a price target of DKK275.00. According to TipRanks, Vosse...

J.P. Morgan Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S (NVO) has launched AMAZE 9, a Phase 3 obesity study title...

Novo Nordisk’s AMAZE 9 Oral Obesity Trial: A New Pill in the Weight-Loss Race

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S (NVO) is running a Phase 1 study called “An NNC6022-0004 ...

Novo Nordisk Adds a New Early-Stage Obesity Drug to Its Pipeline

A federal judge in New Jersey has allowed part of an investor securities lawsuit against Novo Nordisk A/S (NVO) to proceed, while dismissing most o...

Novo Nordisk Lawsuit Ruling Lets Some Securities Claims Move Forward

Analysts are intrested in these 5 stocks: ( ($NVO) ), ( ($LPTH) ), ( ($JSPR) ), ( ($UMAC) ) and ( ($CCEP) ). Here is a breakdown of their recent


Novo, LightPath, Jasper, UMAC, CCEP Trending With Analysts

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk (NVO) has completed a Phase 3 study called “A Study Investiga...

Novo Nordisk Completes Key Oral Semaglutide Study in Japan: What Investors Should Watch

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The SEMA-CardioDiab HUNGARY study, officially titled “SEMA-CardioDiab HUNG...

Novo Nordisk’s SEMA-CardioDiab Hungary Study: What Real-World Oral Semaglutide Data Could Mean for NVO Investors

Novo Nordisk ($NVO) CEO Mike Doustdar is defending the European drug maker’s lawsuit against U.S. rival Eli Lilly ($LLY) over what it alleges is fa...

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)

Shares of Hims & Hers Health ($HIMS), a U.S. telehealth firm, fell over 7% in premarket trading on Tuesday after reporting a more-than-expected Q2 ...

Hims & Hers Stock (HIMS) Slides as GLP-1 Push Swallows Q2 Profits and Widens Loss

Novo Nordisk ( ($NVO) ) just unveiled an announcement. Novo Nordisk reported on August 10, 2026 the latest progress in its ongoing share repurchase...

Novo Nordisk Expands Treasury Position as 2026 Share Buyback Nears DKK 8 Billion

An announcement from Novo Nordisk ( ($NVO) ) is now available. On 6 August 2026, Novo Nordisk disclosed a series of insider transactions involving ...

Novo Nordisk reports vesting of 100th Anniversary restricted shares to board and EVP

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)

In a report released today, Sachin Jain from Bank of America Securities maintained a Hold rating on Novo Nordisk, with a price target of DKK350.00....

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVO	$46.60	-1.92%	6.22M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVO	$46.60	-1.9%	6.22M
3
4
5
6

NVO

Get Novo Nordisk A/S Data in Excel

Get Novo Nordisk A/S Data in Excel